ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
Rhea-AI Summary
ProQR (Nasdaq: PRQR) announced its Annual General Meeting of Shareholders will be held on June 2, 2026 at 15:00 CEST at Allen Overy Shearman Sterling LLP offices in Amsterdam. Relevant meeting documents, including the notice, agenda and explanatory notes, will be available on ProQR's investor website and on the SEC website.
Shareholders who wish to attend must register as described in the notice and agenda.
Positive
- None.
Negative
- None.
News Market Reaction – PRQR
In the May 4 session, PRQR gained 5.81%, reflecting a notable positive market reaction. Argus tracked a peak move of +18.2% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Board nomination | Positive | +1.9% | Nomination of experienced pharma executive to join Board pending AGM approval. |
| Apr 08 | Pipeline update | Positive | +8.2% | Investor event detailing pipeline expansion and upcoming clinical catalysts and timelines. |
| Apr 08 | Partnership & AI strategy | Positive | +7.7% | AI strategy and Ginkgo partnership to support AI-discovered RNA editing candidates. |
| Mar 25 | Event announcement | Positive | +6.0% | Scheduling of virtual investor event focused on Axiomer pipeline and AX-0810 indication. |
| Mar 12 | Earnings & pipeline | Negative | -5.0% | Year-end 2025 financials with net loss alongside cash position and clinical progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across the last five news events, PRQR’s share price consistently moved in the same direction as the apparent tone of the news, with no recorded divergences.
Recent updates for PRQR highlight board-strengthening, pipeline expansion, and financial positioning. On Mar 12, 2026, year-end 2025 results detailed cash of €92.4M and a €42.2M net loss, with clinical progress on AX-0810 and other candidates. Subsequent March and April events emphasized the Axiomer™ RNA editing pipeline, AI-enabled discovery with Ginkgo Bioworks, and multiple upcoming clinical readouts into mid-2027. The April 30, 2026 nomination of Dr. Lykke Hinsch Gylvin ties directly into the AGM referenced in today’s announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda and explanatory notes, are or will be made available in the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Financials and filings” and then “Shareholder meeting”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders that wish to attend should register as described in the notice and agenda.
About Axiomer™
ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding the location and time of the AGM and the availability of all relevant documents and information, our business, technology, strategy, our Axiomer platform and pipeline, including the continued development and advancement of our Axiomer platform and pipeline, the therapeutic potential of our Axiomer RNA editing oligonucleotides, and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
For ProQR Therapeutics N.V.
Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
